Screening for Opioid Misuse Prevention
(STOMP-AI Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores new methods to help individuals manage pain and prevent opioid misuse after hospitalization for a traumatic injury. It focuses on testing various pain coping skills training programs, such as Pain Coping Skills Training - Plus (PCST+), to identify the most effective and acceptable options for participants. The trial seeks individuals hospitalized for a sudden physical injury who have managed their pain with opioids or may be discharged with a prescription for opioid pain relievers. Participants will help determine if these interventions can be used in larger future studies. As an unphased trial, this study offers participants the chance to contribute to innovative pain management strategies that could shape future research and treatment options.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. However, if you are currently prescribed medication for opioid use disorder, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that Pain Coping Skills Training (PCST) and its variations, such as PCST-LITE, PCST-Maintenance, and PCST-Plus, are generally safe for participants. Studies have found these methods help people manage pain better without significant side effects. For instance, both short and long PCST sessions have improved pain control and reduced the need for medication, with no major safety issues reported.
Enhanced Trauma Care Coordination (eTCC) is also part of the trial. Although specific safety data on eTCC is limited, it is designed to help participants manage pain and avoid opioid misuse. This approach typically includes educational and supportive strategies, which are considered low-risk.
The trial is in a "Not Applicable" phase, indicating that the treatments are deemed safe for this type of study. In summary, available evidence supports the safety of these interventions for managing pain and reducing the risk of opioid misuse.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it's exploring new ways to prevent opioid misuse by using tailored pain management techniques. The study focuses on Pain Coping Skills Training (PCST), which is designed to teach patients how to manage pain effectively without relying on opioids. Unlike typical treatments that often involve medication, PCST emphasizes behavioral strategies and coping skills. This approach could offer a safer alternative by reducing the risk of opioid dependency and addressing the psychological aspects of pain management. By adjusting the training based on each participant's risk level, researchers hope to find an effective, personalized prevention method for opioid misuse.
What evidence suggests that this trial's treatments could be effective for preventing opioid misuse?
Research has shown that Pain Coping Skills Training (PCST), one of the treatments in this trial, can help people use fewer opioids. In one study, combining PCST with support for reducing opioid use led to a 43% decrease in opioid doses, compared to a 19% decrease with regular care. Another study found that PCST greatly improved pain management and reduced stress, anxiety, and depression. Enhanced Trauma Care Coordination (eTCC), another treatment option in this trial, also shows promise. It aims to improve the organization and delivery of care, which can help prevent opioid misuse in people recovering from traumatic injuries. Together, these approaches, tested in different arms of this trial, offer ways to prevent opioid misuse after serious injuries.678910
Who Is on the Research Team?
Randy Brown, MD, PhD
Principal Investigator
UW School of Medicine and Public Health
Are You a Good Fit for This Trial?
This trial is for English-speaking individuals hospitalized for a traumatic injury, who received or were prescribed opioids. They must be able to manage their own medications after discharge and have an injury severity score of 9 or more.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one of four interventions: standard Trauma Care Coordination (sTCC), sTCC + Pain Coping Skills Training (PCST-Lite), enhanced Trauma Care Coordination (eTCC), or eTCC + PCST-Lite. Re-randomization may occur at 4 weeks based on risk assessment.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of adverse events and acceptability of the intervention.
What Are the Treatments Tested in This Trial?
Interventions
- Enhanced Trauma Care Coordination (eTCC)
- Pain Coping Skills Training - Brief (PCST-LITE)
- Pain Coping Skills Training - Maintenance (PCST-M)
- Pain Coping Skills Training - Plus (PCST+)
- Standard Trauma Care Coordination (sTCC)
Trial Overview
The study tests several interventions aimed at reducing opioid misuse in trauma patients: Opioid Risk Monitoring, various levels of Pain Coping Skills Training, and different intensities of Trauma Care Coordination. It's a pilot trial to see if these methods are workable and helpful.
How Is the Trial Designed?
12
Treatment groups
Experimental Treatment
Active Control
Participants initially randomized to sTCC who are identified to be at elevated risk for opioid misuse at week 4 will be re-randomized to either PCST-LITE or continued sTCC.
Participants initially randomized to Standard Trauma Care Coordination (sTCC) who are identified to be at elevated risk for opioid misuse at week 4 will be re-randomized to either PCST-LITE or continued sTCC.
Participants initially randomized to eTCC who are identified to be at elevated risk for opioid misuse at week 4 may be re-randomized to receive the same intervention at 4 weeks.
Participants initially randomized to eTCC who are identified to be at elevated risk for opioid misuse at week 4 may be re-randomized to PCST-LITE at 4 weeks.
Participants initially randomized to eTCC who are identified to be at low risk for opioid misuse at week 4 will continue eTCC.
Participants initially randomized to PCST-LITE who are identified to be at elevated risk for opioid misuse at week 4 re-randomized to PCST+.
Participants initially randomized to PCST-Lite who are identified to be at low risk for opioid misuse at week 4 will be assigned to PCST-M.
Participants initially randomized to Pain Coping Skills Training-Lite (PCST-Lite) plus enhanced Trauma Care Coordination (eTCC) who are identified to be at elevated risk for opioid misuse at week 4 may be re-randomized to receive eTCC and Enhanced Pain Coping Skills Training (PCST-Plus).
Participants initially randomized to PCST-Lite plus eTCC who are identified to be at elevated risk for opioid misuse at week 4 may be re-randomized to receive eTCC and Pain Coping Skills Training-Maintenance (PCST-M) at 4 weeks.
Participants initially randomized to PCST-Lite plus eTCC who are identified to be at low risk for opioid misuse at week 4 will then receive eTCC and PCST-M.
Participants initially randomized to PCST-LITE and are not re-randomized to an augmented form of PCST will instead receive PCST-Maintenance (PCST-M).
Participants initially randomized to sTCC who are identified to be at low risk for opioid misuse at week 4 will continued sTCC.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
Wisconsin Partnership Program
Collaborator
Medical College of Wisconsin
Collaborator
Published Research Related to This Trial
Citations
Opioid Use Disorder: Evaluation and Management - NCBI - NIH
Opioid use disorder (OUD) is defined as the chronic use of opioids that causes clinically significant distress or impairment.
Expert providers implement integrated and coordinated ...
Enhancing care integration and coordination to improve patient outcomes in opioid use disorder treatment is a growing focus in the field.
Lessons from the implementation of a trauma center-based ...
This study reports a secondary analysis of a randomized controlled trial implementing an opioid taper support program directed to primary care providers (PCPs)
Comparative Effectiveness of Different Treatment Pathways ...
Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments.
Collaborative Care in the Treatment of Opioid Use Disorder ...
Primary outcomes are six-month rates of opioid use and six-month rates of remission of co-occurring psychiatric disorders. Discussion: The Whole Health Study ...
Screening in Trauma for Opioid Misuse Prevention
Participants initially randomized to Pain Coping Skills Training-Lite (PCST-Lite) plus enhanced Trauma Care Coordination (eTCC) who are identified to be at ...
Lessons from the implementation of a trauma center-based ...
This study reports a secondary analysis of a randomized controlled trial implementing an opioid taper support program directed to primary care providers (PCPs)
8.
library.samhsa.gov
library.samhsa.gov/sites/default/files/opioid-misuse-older-adults-pep24-02-010.pdfPreventing Opioid Misuse and Treating Opioid Use ...
Older adults are susceptible to opioid misuse due to chronic conditions, pain, and increased likelihood of opioid prescriptions. 2% reported misuse in 2022, ...
2022 Academic Detailing to Enhance Overdose Prevention
Academic detailing has been a vital component in efforts to improve opioid prescribing by changing opioid prescribing behavior and utilization of prescription ...
CMS Action Plan to Enhance Prevention and Treatment for ...
This CMS action plan aims to enhance prevention and treatment of OUD, addressing the opioid crisis and the need for changes under Medicare and ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.